Atossa Therapeutics Inc (ATOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -11,927 | -5,878 | -30,094 | -22,340 | -16,111 |
| Depreciation Amortization | 9 | 5 | 23 | 9 | 6 |
| Accounts payable and accrued liabilities | 250 | 424 | -2,159 | -2,247 | -1,943 |
| Other Working Capital | 1,916 | 756 | 1,519 | -131 | -1,548 |
| Other Operating Activity | 523 | -5 | 9,770 | 9,339 | 8,109 |
| Operating Cash Flow | $-9,229 | $-4,698 | $-20,941 | $-15,370 | $-11,487 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -9 | -6 | -14 | -14 | -13 |
| Investing Cash Flow | $-9 | $-6 | $-14 | $-14 | $-13 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 304 | 204 | N/A | N/A | N/A |
| Common Stock Repurchased | N/A | N/A | -1,475 | -1,475 | N/A |
| Financing Cash Flow | $304 | $204 | $-1,475 | $-1,475 | $N/A |
| Beginning Cash Position | 88,570 | 88,570 | 111,000 | 111,000 | 111,000 |
| End Cash Position | 79,636 | 84,070 | 88,570 | 94,141 | 99,500 |
| Net Cash Flow | $-8,934 | $-4,500 | $-22,430 | $-16,859 | $-11,500 |
| Free Cash Flow | |||||
| Operating Cash Flow | -9,229 | -4,698 | -20,941 | -15,370 | -11,487 |
| Capital Expenditure | -9 | -6 | -14 | -14 | -13 |
| Free Cash Flow | -9,238 | -4,704 | -20,955 | -15,384 | -11,500 |